Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Status:
Terminated
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, parallel group, non-blinded phase III trial. Patients with advanced
(locoregional or metastatic) gastric cancer not previously treated with chemotherapy for this
stage will be randomized in a 1:1 ratio to receive low-TOX (arm A) or EOX (arm B).
Randomization will be stratified by performance status (ECOG 0, 1 and 2).
Phase:
Phase 3
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente